Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786971 | 1.00 | HSD17B10 (0.36) | HSD17B10TP53KMT2AMEN1EGFR | |
| SCHEMBL7786868 | 0.77 | PLK1 (0.40) | HSD17B10TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL7786870 | 0.77 | PLK1 (0.40) | HSD17B10TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL6706898 | 0.73 | PRSS1 (0.42) | HSD17B10TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL6706899 | 0.73 | PRSS1 (0.42) | HSD17B10TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL13598174 | 0.73 | RECQL (0.46) | HSD17B10TP53KMT2ALMNAMAPT | |
| SCHEMBL7790720 | 0.71 | ALDH1A1 (0.33) | HSD17B10TP53KMT2AMEN1EGFR | |
| SCHEMBL7790716 | 0.71 | ALDH1A1 (0.33) | HSD17B10TP53KMT2AMEN1EGFR | |
| SCHEMBL10753245 | 0.70 | HSD17B10 (0.46) | HSD17B10TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL6706099 | 0.70 | HSD17B10 (0.46) | HSD17B10TP53KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | CIBA SPEICIALTY CHEMICALS CORP. | 2001-11-01 | — | — | US | disclosed |
| US-6017675-A | POLYMERIZATION CATALYST | CIBA SPECIALTY CHEMIALS CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | QSOX1, HAO2, PAH | HSD17B10 302/4885TP53 4466/4885KMT2A 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.